BusinessScott VanderWel Joins PCI Synthesis as Business Development ManagerBy Nasdaq OMXNov 15, 2017, 3:15 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Patrick Walsh to Board of Directors of Peregrine and Avid BioservicesBy Nasdaq OMXOct 24, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid BioservicesBy Nasdaq OMXOct 19, 2017, 12:05 PM UTC
BusinessAvid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius® 2,000-Liter Single-Use Bioreactors in Its Myford FacilityBy Nasdaq OMXSep 25, 2017, 12:05 PM UTC
BusinessAvid Bioservices to Exhibit at 2017 BioProcess International Conference & ExhibitionBy Nasdaq OMXSep 19, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent DevelopmentsBy Nasdaq OMXSep 11, 2017, 8:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid BioservicesBy Nasdaq OMXSep 11, 2017, 12:05 PM UTC
BusinessPeregrine to Report Financial Results for First Quarter of Fiscal Year 2018 After Market Close on September 11, 2017By Nasdaq OMXSep 6, 2017, 8:05 PM UTC
